Abstract
Lawall et al. report a phase IIa randomised, placebo controlled feasibility trial investigating the preliminary efficacy of sublingual glyceryl trinitrate (GTN) powder in patients with stable Fontaine 2B intermittent claudication (IC).1 This well executed study aimed to develop a new pharmaceutical treatment to reduce IC symptomatology, and the authors should be congratulated for their rigorous scientific approach. The unmet medical need is large within this treatment space, and successful drug development efforts therein will have the potential to change the lives of millions given the sizeable population living with peripheral arterial disease (PAD).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Vascular and Endovascular Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
